Today, Monday, a European Union spokesman said that the agreement between the European Commission and Pfizer / BioNTech, according to which the European Union will purchase 300 million additional doses of the Coronavirus vaccine, is final.
According to press reports, a spokesperson familiar with the details of the session confirmed that the European Commission Commissioners’ Authority has approved a new contract for the procurement of vaccines, writes MTI.
Ursula von der LeyenThe president of the European Commission announced in January that the European Union’s Executive Council was preparing to conclude a second contract with Pfizer and BioNTech.
The European Commission had already signed a contract to supply 300 million doses of the jointly developed vaccine between the US pharmaceutical company Pfizer and the German biotechnology company BioNTech at the end of November, and on December 21 it also agreed to use the vaccine in the European Union. Vaccinations against Coronavirus began in member countries at Christmas.
In addition to Pfizer / BioNTech, the European Commission has so far identified Moderna (160 million doses), AstraZeneca (400 million doses), Sanofi-GSK (300 million doses), Johnson and Johnson (400 million doses), BioNTech-Pfizer (600 million doses) ) And CureVac (405 million doses) signed vaccine contracts. It also concluded talks with Novavax in mid-December regarding a possible vaccine against the Coronavirus, a planned contract that will allow the European Union to purchase 100 million doses and up to 100 million additional doses of the vaccine.